Advancis Files NDA For Pulsatile Amoxicillin
This article was originally published in The Pink Sheet Daily
Executive Summary
The company does not rule out the possibility of copromoting the first once-daily formulation of the antibiotic as a way of expanding its sales force if Amoxicillin Pulsys is approved.
You may also be interested in...
Advancis Gets “Refuse To File” Letter For Pulsatile Amoxicillin NDA
Firm may need to manufacture commercial-sized quantities of antibiotic in order for FDA to accept the submission.
Advancis Gets “Refuse To File” Letter For Pulsatile Amoxicillin NDA
Firm may need to manufacture commercial-sized quantities of antibiotic in order for FDA to accept the submission.
Advancis Targeting Pharmacies In Effort To Energize Keflex 750 Sales
In sit-downs with retail pharmacy chains, Advancis is offering price incentives and arguing that the new cephalexin strength needs to be stocked because it has no generic equivalent.